![]() |
![]() |
| Korean J Med > Volume 101(5); 2026 > Article |
|
| Characteristic | Arexvy | Abrysvo | mResvia |
|---|---|---|---|
| Platform | Recombinant prefusion F protein with AS01E adjuvant (MPL and QS-21) | Bivalent recombinant prefusion F protein (subgroups A and B) | mRNA encoding prefusion F protein, lipid nanoparticle formulation |
| Administration | Single 0.5 mL intramuscular dose | Single 0.5 mL intramuscular dose | Single 0.5 mL intramuscular dose |
| Lyophilized powder plus diluent, reconstituted before use | Lyophilized powder plus diluent, reconstituted before use | Prefilled syringe, ready to use | |
| FDA-approved indication | Adults ≥ 60 years (May 2023) | Adults ≥ 60 years (May 2023) | Adults ≥ 60 years (May 2024) |
| Adults 50-59 years at increased riska (June 2024) | Pregnant individuals at 32-36 weeks gestation (August 2023) | Adults 18-59 years at increased risk (June 2025) | |
| Adults 18-49 years at increased risk (March 2026) | Adults 18-59 years at increased risk (October 2024) | ||
| Efficacy in pivotal trialsb | AReSVi-006 (n = 24,966) [4,7] | RENOIR (n = 34,284) [9] | ConquerRSV (n = 35,541) [13,14] |
| Adults ≥ 60 years | Adults ≥ 60 years | Adults ≥ 60 years | |
| RSV-LRTD 82.6% (CI, 57.9-94.1)c | RSV-LRTD ≥ 2 symptoms 66.7% (CI, 28.8-85.8) | RSV-LRTD ≥ 2 symptoms 83.7% (CI, 66.0-92.2) | |
| Severe RSV-LRTD 94.1% (CI, 62.4-99.9) | RSV-LRTD ≥ 3 symptoms 85.7% (CI, 32.0-98.7) | RSV-LRTD ≥ 3 symptoms 82.4% (CI, 34.8-95.3) | |
| Cumulative over 3 seasons 62.9% (CI, 46.7-74.8) | MATISSE (n ≈ 7,400) [5] | ≥ 2 symptoms at 8.6 months follow-up 63.3% (CI, 48.7-73.7) | |
| Pregnant individuals | |||
| Severe infant RSV-LRTD 90 days 81.8% (CI, 40.6-96.3) | |||
| Severe infant RSV-LRTD 180 days 69.4% (CI, 44.3-84.1) | |||
| Reactogenicityd in pivotal trials | Injection-site pain ≈ 60% (placebo ≈ 10%), fatigue 34%, myalgia 29%, headache 28%, arthralgia [4] | Injection-site pain ≈ 10%, fatigue ≈ 16%, headache ≈ 13% | Injection-site pain ≈ 56% (placebo ≈ 14%), fatigue, headache, myalgia, arthralgia [13] |
| Differences from placebo were small [9] | |||
| Safety findings and regulatory actionse | GBS signal in post-marketing surveillance (≈ 7 excess cases per million doses) | GBS signal in post-marketing surveillance (≈ 9 excess cases per million doses) | No GBS reported to date |
| FDA warning added January 2025 [21] | FDA warning added January 2025 [21] | No labelled warning | |
| Preterm birth 5.7% vs. 4.7% (placebo) in the MATISSE trial | Surveillance data more limited than for the protein-based vaccines, so the absence of a signal does not establish the absence of risk | ||
| Not statistically significant [5] | |||
| Approval restricted to 32-36 weeks gestation as a precautionary measure | |||
| Regulatory status in Koreaf | Licensed 2024 | Under review by MFDS | Licensed December 2025 (adults ≥ 60 years, 18-59 years at increased risk) |
| Expanded to adults 18-49 years at increased risk (July 2026) | Launch timeline not confirmed | ||
| Currently the only RSV vaccine marketed in Korea | Not yet launched | ||
| Distinguishing features | First licensed RSV vaccine | Only vaccine approved for maternal immunization | Only mRNA-based RSV vaccine |
| Only adjuvanted product | Infant protection via transplacental antibody transfer | Ready-to-use syringe | |
| Efficacy shown over three consecutive seasons | Combination vaccine with influenza under development |
AS01E, Adjuvant System 01E; MPL, monophosphoryl lipid A; QS-21, Quillaja saponaria Molina fraction 21; FDA, United States Food and Drug Administration; RSV-LRTD, RSV-associated lower respiratory tract disease; CI, confidence interval; GBS, Guillain-Barré syndrome; RSV, respiratory syncytial virus; MFDS, Ministry of Food and Drug Safety.
a At increased risk refers to the risk conditions defined by the Advisory Committee on Immunization Practices and listed in the footnote to Table 2.
b Efficacy estimates are not directly comparable across trials, as endpoint definitions, study populations, and study periods differed, and no head-to-head trial has been conducted.
c Confidence levels differ across trials because each pivotal trial applied an alpha-spending adjustment for interim analyses. Intervals are therefore reported as “CI” without a stated level, and readers should consult the original publications for the exact levels.
d Reactogenicity rates are likewise not directly comparable across products, as the pivotal trials used different methods of solicitation and different definitions.
e In a propensity-matched cohort study, RSV vaccination was not associated with new-onset or recurrent atrial fibrillation; that analysis was not product-specific [23].
| Patient group | Vaccines with an approved indication | Evidence base | Clinical considerations |
|---|---|---|---|
| Adults ≥ 75 years | All three vaccines | Randomized controlled trials in adults ≥ 60 years [4,9,13], supported by post-marketing effectiveness studies [19] | ACIP recommends vaccination regardless of risk factors [6] |
| Single dose | |||
| Revaccination not currently recommended | |||
| Only Arexvy is currently obtainable in Korea | |||
| Adults 50-74 years with risk conditionsa | All three vaccines | Direct trial evidence for adults ≥ 60 years [4,9,13] | ACIP recommends vaccination if ≥ 1 risk condition is present [6] |
| Immunobridging for adults 50-59 years [8] | Risk conditions are narrower than commonly assumed, particularly for diabetes and chronic kidney disease | ||
| Hypertension alone does not qualify | |||
| Adults 18-49 years with risk conditions | All three vaccines | Immunobridging from older adults [8,12,15] | Not currently included in ACIP recommendations |
| Arexvy (FDA in March 2026; Korea in July 2026) | No efficacy trial in this age group | Individualized decision based on the severity of the underlying condition | |
| Abrysvo and mResvia through their 18-59 years indications | |||
| Pregnant individuals | Abrysvo only | MATISSE trial [5] | Administer at 32-36 weeks gestation |
| Infant protection through 6 months of age | Not available in Korea, as Abrysvo is not yet licensed | ||
| Nirsevimab, available since February 2025, is currently the only means of protecting infants in Korea | |||
| Immunocompromised patients | All three vaccines (as part of the definition of increased risk) | Excluded from all pivotal trials | Not live vaccines |
| Evidence from observational studies | Not contraindicated | ||
| IDSA reports a 70% (CI, 66-73)b reduction in RSV-associated hospitalization [18] | Antibody responses may be attenuated | ||
| Vaccinate before starting immunosuppression where feasible | |||
| Optimal timing by type of immunosuppression is not established | |||
| Individualize | |||
| Patients with a history of GBS | No absolute contraindication | Fewer than 10 excess cases per million doses for the protein-based vaccines [21] | Weigh the excess risk from vaccination against the risk from RSV infection |
| RSV infection itself is associated with a 2- to 2.5- fold increase in GBS risk [22] | Individualized decision-making is appropriate | ||
| No GBS signal for mResvia, although surveillance data remain limited |
ACIP recommendations reflect United States public health policy and do not automatically apply to clinical practice in Korea. Prescribing decisions in Korea should additionally take account of MFDS-approved indications, product availability, and cost, as RSV vaccines are not included in the National Immunization Program and are paid for entirely out of pocket. Status is current as of July 2026.
ACIP, Advisory Committee on Immunization Practices; FDA, United States Food and Drug Administration; IDSA, Infectious Diseases Society of America; CI, confidence interval; RSV, respiratory syncytial virus; GBS, Guillain-Barré syndrome; MFDS, Ministry of Food and Drug Safety.
a Chronic lung or respiratory disease; chronic cardiovascular disease, excluding isolated hypertension; end-stage renal disease or dialysis dependence; diabetes mellitus with end-organ damage or requiring insulin or a sodium-glucose cotransporter-2 inhibitor; chronic liver disease; chronic haematologic disease; neurologic or neuromuscular disease causing impaired airway clearance or respiratory muscle weakness; severe obesity (body mass index ≥ 40 kg/m2); moderate or severe immunocompromise; residence in a long-term care facility; frailty; and other chronic conditions that, in the judgement of the treating clinician, increase the risk of severe respiratory infection.

![]() |
![]() |